Trial Profile
An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary) ; Hexyl aminolevulinate (Primary) ; Hexyl aminolevulinate (Primary) ; Hexyl aminolevulinate (Primary)
- Indications Bladder cancer; Cervical intraepithelial neoplasia; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors PhotoCure
- 24 Jan 2010 New trial record